---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001236"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:30:31.898869+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma delays Q2 FY2023 filing due to warrant accounting matter; believes no impact on revenue, cash, or EBITDA

## Summary
- Delayed filing of Form 10-Q for quarter ended Dec 31, 2022 pending management review of warrant accounting from prior financings.
- Company states the matter will not affect assets, cash, revenue, cost of goods sold, operating expenses, loss from operations, or adjusted EBITDA.
- Quarterly conference call rescheduled; company intends to file the quarterly report as soon as practicable.
- No restatement or adjustment to previously reported financial metrics expected.

## SEC filing metadata
- accession: 0001558370-23-001236
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01, 99.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023001236/0001558370-23-001236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023001236/aytu-20230214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001236
- JSON: https://secwatch.observer/filing/0001558370-23-001236.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.